Actinium clears path for fundraising and listing to advance alpha/MAb therapies
This article was originally published in Scrip
Executive Summary
The Newark, New Jersey-based privately held company Actinium Pharmaceuticals, which is developing drugs combining cell-targeting antibodies with alpha-emitting radioisotopes to treat cancer, has secured approval from its shareholders to raise up to $25 million and seek a public listing.
You may also be interested in...
Actinium Seeks to Disrupt As Radioligand Candidate Succeeds In Pivotal Pre-Transplant AML Trial
The US firm’s lead asset has impressed as a conditioning regimen for AML patients undergoing bone marrow transplant, boding well for an ongoing US filing as the firm works to disrupt the transplant space across a range of blood cancers.
20 Voices: What Does 2024 Hold For Biopharma?
20 executives in the biopharma industry outline their view of key trends this year. A selection of commentary from a broad industry survey by Scrip.
Scrip Asks…What Does 2024 Hold For Biopharma? Part 6: Therapeutic Area Advances
More than 100 biopharma executives and experts told Scrip their predictions for therapeutic area advances in the coming year. The recent commercial success of GLP-1s in diabetes and obesity and their potential in further disease areas fuelled excitement around the metabolic space. Expectations were also positive in neurology following the launch of Leqembi for Alzheimer’s disease in 2023, while the multiple opportunities to improve cancer treatment kept oncology top of the pile overall.